Under construction – not a live service

Skip to content

Frontlight Research

Trial site

New York, NY

New York, New York 10022, United StatesNot linked to an institution yet

1running trial

The trials here

What the trial at this site is about, from its registry record.

Conditions: Diabetic eye disease

Running trials

Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error

Under construction, not live – New York, NY: trial site – Frontlight Research